Sugi Predict

Sugi Predict / Compounds / SCHEMBL446874

SCHEMBL446874

SCHEMBL446874

Fc1ccc2nc(Cl)ncc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ BACE1 P56817 1/20 0.46
▸ MAPT P10636 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ CASP3 P42574 2/20 0.38
▸ SENP8 Q96LD8 2/20 0.38
▸ SENP7 Q9BQF6 2/20 0.38
▸ SENP6 Q9GZR1 2/20 0.38
▸ PDE3B Q13370 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ KCNQ3 O43525 1/20 0.37
▸ KCNQ2 O43526 1/20 0.37
▸ KCNQ5 Q9NR82 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ AXL P30530 1/20 0.35
▸ GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558609 0.84 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2BACE1MAPT
SCHEMBL30354091 0.79 HTR3A (0.50) KDM4EALDH1A1SMN1; SMN2BACE1PDE3B
SCHEMBL2595849 0.79 HTR3A (0.50) KDM4EALDH1A1SMN1; SMN2BACE1PDE3B
SCHEMBL4849482 0.79 TRPA1 (0.44) KDM4EALDH1A1SMN1; SMN2
SCHEMBL1570789 0.76 HTT (0.49) KDM4EALDH1A1SMN1; SMN2BACE1L3MBTL1
SCHEMBL2853685 0.76 KDM4E (0.46) KDM4EBACE1MAPTL3MBTL1CASP3
SCHEMBL13362651 0.76 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2HTR3A
SCHEMBL31391518 0.76 BACE1 (0.46) KDM4EBACE1MAPTL3MBTL1CASP3
SCHEMBL858595 0.76 ALDH1A1 (0.50) KDM4EALDH1A1SMN1; SMN2BACE1MAPT
SCHEMBL1571191 0.76 ALDH1A1 (0.46) KDM4EALDH1A1SMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1894234-A Dipeptidyl peptidase inhibitors SYRRX INC (JP) 2007-01-10 — — CN claimed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 — — US disclosed
US-12258354-B2 AhR modulators IDEAYA BIOSCIENCES, INC. (US) 2025-03-25 — — US disclosed
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 — — US disclosed
EP-3749669-B3 AHR MODULATORS IDEAYA BIOSCIENCES INC (US) 2024-09-04 — — EP disclosed
CN-115785074-B PARP7 inhibitors and uses thereof 诺沃斯达药业(上海)有限公司 2024-05-07 — — CN disclosed
CN-111683950-B AhR modulators 伊迪亚生物科学有限公司 2024-04-16 — — CN disclosed
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-04-04 — — US disclosed
EP-4338737-A1 PARP7 INHIBITOR AND USE THEREOF Novostar Pharmaceuticals, Ltd. (CN) 2024-03-20 — — EP disclosed
WO-2023185073-A1 PARP7 INHIBITOR AND USE THEREOF 诺沃斯达药业(上海)有限公司 2023-10-05 — — WO disclosed
US-20080132490-A1 Substituted diazepan orexin receptor antagonists MERCK SHARP & DOHME LLC 2008-06-05 — — US disclosed
US-20080132490-A1 Substituted diazepan orexin receptor antagonists MERCK SHARP & DOHME LLC 2008-06-05 — — US disclosed
US-20080132490-A1 Substituted diazepan orexin receptor antagonists MERCK SHARP & DOHME LLC 2008-06-05 — — US disclosed
WO-2008008517-A2 BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-01-17 — — WO disclosed
WO-2008008517-A2 BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-01-17 — — WO disclosed
CN-1894234-A Dipeptidyl peptidase inhibitors SYRRX INC (JP) 2007-01-10 — — CN disclosed
CN-1044245-C Tricyclic Dicarbonyl derivatives HAFFMANN LA ROCHE AG F (DE) 1999-07-21 — — CN disclosed
CN-1149295-A Tricyclic Dicarbonyl derivatives HOFFMANN LA ROCHE (CH) 1997-05-07 — — CN disclosed
EP-0248554-B1 HETEROCYCLIC COMPOUNDS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-03 — — EP disclosed
EP-0248554-A2 Heterocyclic compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132490-A1 Substituted diazepan orexin receptor antagonists HCRTR2, HCRTR1, CRHR1 KDM4E 1573/4885ALDH1A1 3194/4885SMN1; SMN2 2179/4885
US-12258354-B2 AhR modulators AHR, ARNT, RORB KDM4E 485/4885ALDH1A1 579/4885SMN1; SMN2 4221/4885
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 KDM4E 1710/4885ALDH1A1 647/4885SMN1; SMN2 1592/4885
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS HCRTR2, HCRTR1, OXTR KDM4E 454/4885ALDH1A1 3132/4885SMN1; SMN2 3009/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR KDM4E 454/4885ALDH1A1 3132/4885SMN1; SMN2 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.